Sentinel lymph node biopsy as the new standard of care in the surgical treatment for breast cancer

Expert Review of Anticancer Therapy

Volumn 6, Issue 10, 2006, Pages 1503-1515

  Ferrari, Alberta ^a   Rovera, Francesca ^a   Dionigi, Paolo ^b   Limonta, Giorgio ^a   Marelli, Marina ^a   Ciani, Isabella Besana ^a   Bianchi, Veronica ^a   Vanoli, Cristiana ^a   Dionigi, Renzo ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Breast cancer; Breast surgery; Clinical controversies; Sentinel node biopsy; Sentinel node micrometastasis; Technical controversies

Indexed keywords

ALBUMIN TC 99M; ANTINEOPLASTIC AGENT; TECHNETIUM SULFUR COLLOID TC 99M; TRACER;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DRUG HYPERSENSITIVITY; FEASIBILITY STUDY; HUMAN; LYMPH NODE DISSECTION; MASTECTOMY; META ANALYSIS; MINIMALLY INVASIVE SURGERY; MORBIDITY; MULTIPLE CANCER; PATHOPHYSIOLOGY; PATIENT CARE; PREGNANCY; REVIEW; SENTINEL LYMPH NODE BIOPSY; STANDARDIZATION; SURGICAL TRAINING; SYSTEMATIC REVIEW; TREATMENT INDICATION; TUMOR VOLUME; VALIDATION STUDY;

BREAST NEOPLASMS; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; SENTINEL LYMPH NODE BIOPSY;

EID: 33750713330     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.10.1503     Document Type: Review

References (110)

1. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer 39, 456-466 (1977).
2. Morton DL, Wen DR, Wong JH et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch. Surg. 127, 392-399 (1992).
3. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 2, 335-339 (1993).
4. Krag DN, Weaver D, Ashikaga T et al. The sentinel lymph node in breast cancer: a multicentric validation study N. Engl, J. Med. 339, 941-946 (1998).
5. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann. Surg. 220, 391-398 (1994).
6. Giuliano AE, Jones RC, Brennan M et al. Sentinel lymphadenectomy in breast cancer. Clin. Oncol. 15, 2345-2350 (1997).
7. Albertini JJ, Lyman GH, Cox C et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 276, 1818-1822 (1996).
8. Veronesi U, Paganelli G, Galimberti V et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. Lancet 349, 1864-1867 (1997).
9. Veronesi U, Paganelli G, Viale G et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: Results in a large series. J Natl Cancer Inst. 91. 368-373 (1999).
10. Schwartz GF, Giuliano AE, Veronesi U. Proceedings of the Consensus Conference on the Role of Sentinel Lymph Node Biopsy in Carcinoma of the Breast, April 19-22, 2001. Philadelphia, PA, USA. Cancer 94(10), 2542-2547 (2002).
11. Senn HJ, Thurlimann B, Goldhirsch A et al. Comments on the St. Callen Consensus 2003 on the primary therapy of early breast cancer. Breast 12, 569-582 (2003).
12. Lyman GH, Giuliano AE, Somerfield MR et al. American Society of Clinical Oncology Guideline Recommendations for sentinel lymph node biopsy in early-stage breast cancer. J. Clin, Oncol 23 (30), 7703-7720 (2005).
13. Veronesi U, Paganelli G, Viale G et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N. Engl. J. Med. 349, 546-553 (2003).
14. Flessig A, Fallowfield LJ, Langridge CI et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomized trial comparing sentinel lymph node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res. Treat. 1-15 (2005).
15. Julian TB, Anderson S, Brown A et al. Continued technical results of NSABP B-32: does a positive sentinel node biopsy require an axillary dissection? Breast Cancer Res. Treat. (2005).
16. Purushotham AD, Upponi S, Klevesath MB et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J. Clin. Oncol. 23, 4312-4321 (2005)
17. Naik AM, Fey J, Gemignani M et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann. Surg. 240(3), 462-468 (2004).
18. Veronesi U, Galimberd V, Manani L et al. Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissecton. Eur. J. Cancer 41(2), 197-198 (2005).
19. Krag DN, Julia TB, Harlow SP et al. NSABP-32: Phase III, randomized trial comparing axillary resection with sentinel lymph node dissection: a description of the trial. Ann. Surg. Oncol 11. 208S-210S (2004).
20. Gill PG. Sentinel lymph node biopsy versus axillary clearance in operable breast cancer: the RACS SNAC trial, a multicenter randomized trial of the Royal Australian College of Surgeons (RACS) Section of Breast Surgery, in collaboration with the National Health and Medical Research Council Clinical Trials Center. Ann. Surg. Oncol. 11, 216S-221S (2004).
21. Cody HS III, Fey J, Alchurst T et al. Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures. Ann. Surg. Oncol. 8, 13-19 (2001).
22. Schirrmeister H, Kotzerke J, Vogl F et al. Prospective evaluation or factors influencing success rates of sentinel node biopsy in 814 breast cancer patients. Cancer Biother. Radiopharm. 19(6), 784-790 (2004).
23. Tuttle TM. Sentinel lymph node biopsy. Preferred method of axillary staging for breast cancer. Minerva Ginecol. 57(3), 293-303 (2005).
24. Kim SC, Kim DW, Moadel RM et al. Using the intraoperative hand held probe without lymphoscintigraphy or using only dye correlates with higher sensory morbidity following sentinel lymph node biopsy in breast cancer: a review of the literature. World J. Surg. Oncol. 3(1), 64 (2005).
25. Chagpar AB, Martin RC, Scoggins CR et al. Factors predicting failure to identify a sentinel lymph node in breast cancer. Surgery 138(1), 56-63 (2005).
26. Teal CB, Slocum JF, Akin EA, Kelly TA. Correlation of lymphoscintigraphy with the number of sentinel lymph nodes identified intraoperatively in patients with breast cancer. Am. J. Surg 190 (4), 567-569 (2005).
27. Martin RC, Derossis AM, Fey J et al. Intradermal isotope injection is superior to intramammary in sentinel node biopsy for breast cancer. Surgey 130, 432-438 (2001).
28. 9m-tc sulphur colloid is effective in the detection of breast sentinel nodes. Am. Surg. 68. 1083-1087 (2002)
29. McMasters K, Wong S, Martin R et al. Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multiinstutional study. Ann. Surg. 233(5), 676-687 (2001).
30. 9mTc facilitates sentinel lymph node identification. Ann Surg.. Oncol. 9(1), 77-81 (2002).
31. Klimberg VS, Rubio IT, Henry R et al. Subareolar versus peritumoral injection for location of sentinel lymph node. Ann. Surg. 229(6), 860-864 (1999).
32. Borgstein PJ, Meijer S, Pijpers RJ, van Diest PJ. Functional lymphatic anatomy for sentinel node biopsy in breast cancer. Ann. Surg. 232(1), 81-89 (2000).
33. Bauer TW, Spitz FR, Callans LS et al. Subareolar and peritumoral injection identify similar sentinel nodes for breast cancer. Ann. Surg. Oncol. 9(2), 169-176 (2002).
34. 9m sulfur colloid. J. Am. Coll. Surg. 193(6), 601-608 (2001).
35. Chapgar A, Martin RC III, Chao C et al. Validation of subareolar and periareolar injection techniques for breast sentinel lymph node biopsy. Arch. Surg. 139, 614-620 (2004).
36. Smith LF, Cross MJ, Klimberg VS. Subareolar injection is a better technique for sentinel lymph node biopsy. Am. J. Surg. 180, 434-438 (2000).
37. Sanidas E, deBree E, Tsiftsis DD. How many cases are enough for accreditation in sentinel lymph node biopsy in breast cancer? Am. J. Surg. 185, 202-210 (2003).
38. Posther KE, McCall LM, Blumencranz PW et al. Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for eary-stage breast cancer. Ann. Surg. 242(4), 593-602 (2005).
39. Rutgers EJ. Guidelines to assure quality in breast cancer surgery. Eur. J. Oncol. 31(6). 568-576 (2005).
40. McMasters KM. Appropriate surgeon training for breast cancer sentinel lymph node biopsy. Am. J. Surg. 186(3), 313-314 (2003)
41. Sanidas E, Daskalakis M, Sbyrakis N et al. Modifications of the learning curve guidelines for breast cancer sentinel node biopsy. Eur. J. Surg. Oncol. 31, 357-363 (2005)
42. Mansel R. Sentinel node biopsy and beyond. 5th European Breast Cancer Conference. Nice, 21-25 March 2006. Abstract book: Eur. J. Cancer 4(2), 114, N228.
43. Giuliano AE, Dale PS, Turner RR et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann. Surg. 222(3), 394-401 (1995).
44. Cserni G, Bianchi S, Boecker W et al. Improving the reproducibility of diagnosing micrometastases and isolated tumor cells. Cancer 103(2), 358-367 (2005).
45. Singletary SE, Allred C. Ashley P et al. Revision of the American Joint Commettee on Cancer staging system for breast cancer. J. Clin. Oncol. 20, 3628-3636 (2002).
46. UICC TNM Classification of Malignant Tumors, 6th Edition. Sobin LH, Wittekind C (Eds). John Wiley & Sons. Inc., NY, USA (2002).
47. Hermanek P, Hutter RVP, Sobin LH et al. Classification of isolated tumor cells and micrometastasis. Cancer 86, 2668-2673 (1999)
48. th edition of the American Joint Commettee of Cancer staging manual. Cancer 98, 2740-2741 (2003).
49. Cserni G, Amendoeira I, Apostolikas N et al. Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines. Eur. J. Cancer 39 (12), 1654-1667 (2003).
50. Viale G, Maiorano E, Mazzarol G et al. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer 92(6), 1378-1384 (2001).
51. Brogi E, Torres-Matundan E, Tan LK et al. The results of frozen sections, touch preparation, and cytological smear are comparable for intraoperative examination of sentinel lymph nodes: a study in 133 breast cancer patients. Ann. Surg. Oncol. 12(2), 173-180 (2005).
52. Van Diest PJ, Torrenga H, Borgstein PJ et al. Reliability of intraoperative frozen sections and imprint cytological investigation of sentinel lymph nodes in breast cancer. Histopathology 35, 14-18 (1999).
53. Luini A, Gatti G, Zurrida S et al. The sentinel lymph node biopsy under local anesthesia in breast carcinoma: experience of the European Institute of Oncology and impact on quality of life. Breast Cancer Res. Treat. 89, 69-74 (2005).
54. Ferrari A, Rovera F, Dionigi P et al. Multifocality and multicentricity are not contraindications for sentinel lymph node biopsy (SLNB) in breast cancer surgery. World J. Surg. Oncol. (2006) (In Print).
55. Estourgie SH, Nieweg OE, Valdés Olmos RA et al. Lymphatic drainage patterns from the breast. Ann. Surg. Oncol. 10, S54 (2003).
56. Roumen RM, Geuskens LM, Valkenburg JG. In search of the true sentinel node by different injection techniques in breast cancer patients. Eur. J. Surg. Oncol. 25, 347-351 (1999).
57. Park C, Seid P, Morita E et al. Internal mammary sentinel lymph node mapping for invasive breast cancer: implications for staging and treatment. Breast J. 11 (1), 29-33 (2005).
58. Veronesi U, Cascinelli N, Greco M et al. Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes. Ann. Surg. 202, 702-707 (1985).
59. Noguchi M, Taniya T, Koyasachi N et al. Risk of internal mammary lymph node metastases and its prognostic value in breast cancer patients. J. Surg. Oncol. 52, 26-30 (1993)
60. Shen J, Hunt KK, Mirza NQ el al. Intramammary lymph node metastases are an independent predictor of poor outcome in patients with breast carcinoma. Cancer 101, 1330-1337 (2004).
61. Veronesi U, Marubini E, Mariani L et al. The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomized trial. Eur. J. Cancer 35, 1320-1325 (1999).
62. Galimberti V, Veronesi R Arnone P et al. Stage migration after biopsy or internal mammary chain lymph nodes in breast cancer patients. Ann. Surg, Oncol. 9. 924-928 (2002).
63. Tanis PJ, Nieweg OE, Valdés Olmos RA et al. Impact of non-axillary sentinel node biopsy on staging and treatment of breast cancer patients. Br. J Cancer 87, 705-710 (2002).
64. Paredes P, Vidal-Sicart S, Zanòn G et al. Clinical relevance of sentinel lymph nodes in the internal mammary chain in breast cancer patients. Eur. J. Nucl. Med. Mol. Imaging 32(11), 1283-1287 (2005).
65. Farrus B, Vidal-Sicart S, Velasco M et al. Incidence of internal mammary node metastases after a sentinel lymph node technique in breast cancer and its implications in the radiotherapy plan. Int. J. Radiat. Oncol. Biol. Phys. 60(3), 715-721 (2004).
66. Noguchi M. Internal mammary sentinel node biopsy for breast cancer: Is it practicable and relevant? Oncol. Rep. 9. 461-468 (2002).
67. Goldhirsch A, Glick JH, Gelber RD et al. Panel members: Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann. Oncol. 16(10), 1569-1583 (2005).
68. Kuerer HM and Newman LA. Lymphatic mapping and sentinel lymph node biopsy for breast cancer: developments and resolving controversies. J. Clin. Oncol. 23(8), 1698-1705 (2005).
69. Leidenius MH, Krogerus LA, Toivonen TS et al. Sentinel node biopsy is not sensible in breast cancer patients with large primary tumors. Eur. J. Surg. Oncol. 31(4), 364-368 (2005).
70. Borgstein F, Pijpers R, Comans E et al. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J. Am. Coll. Surg. 186(3), 275-283 (1998).
71. Boolbol SK, Fey JV, Borgen PT et al. Intradermal isotope injection: a highly accurate method of lymphatic mapping in breast carcinoma. Ann. Surg. Oncol. 8, 20-24 (2001).
72. Goyal A, Douglas-Jones A, Newcombe R et al. Objective assessment of sentinel node tumor burden and its impact on sentinel lymph node localization in breast cancer. Eur. J. Cancer 4(2), 79(N.125) (2006).
73. Chung MH, Ye W, Giuliano AE. Role of sentinel lymph node dissection in the management of large (> or = 5 cm) invasive breast cancer. Ann. Surg, Oncol. 8, 688-692 (2001).
74. Fisher B. Wolmark N, Bauer M et al The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg. Gynecol. Obstet. 152, 765-772 (1981).
75. Specht MC, Fey JV, Borgen PI et al. Is the clinically positive axilla in breast cancer really a contraindication to sentinel lymph node biopsy? J. Am. Coll. Surg. 200(1), 10-14 (2005).
76. Anderson BO. Sentinel lymphadenectomy in breast cancer: An update on the NCCN Practice Guidelines. J. Natl Compr. Cancer Network 1 (Suppl. 1), S64-S70 (2003).
77. Ozmen V, Muslumanoglu M, Cabioglu N et al. Increased false-negative rates in sentinel lymph node biopsies in patients with multi-focal breast cancer. Breast Cancer Res. Treat. 76, 237-244 (2002).
78. Kumar R, Jana S, Heiba SI et al. Retrospective analysis of sentinel node localization in multifocal, multicentric, palpable, or nonpalpable breast cancer. J. Nucl. Med. 44(1), 7-10 (2003).
79. Tousimis E, Van Zee KJ, Fey JV et al. The accuracy of sentinel lymph node biopsy in multicentric and multifocal invasive breast cancers. J. Am. Coll. Surg. 197(4), 529-535 (2003).
80. Kumar R, Potenta S, Alavi A. Sentinel lymph node biopsy in multifocal and multicentric breast cancer. J. Am. Coll. Surg. 198(4), 674-675 (2004).
81. Fernandez K, Swanson M, Verbanac K, Tafra L. Is sentinel lymphadenectomy accurate in multifocal and multicentric breast cancer (abstract). Ann. Surg. Oncol. 9, S16-S17 (2002).
82. Goyal A, Newcombe RG, Mansel RE. Sentinel lymph node biopsy in patients with multifocal breast cancer. Eur. J. Surg. Oncol. 30, 475-479 (2004).
83. Knauer M, Konstantiniuk P. Riegler-Keil M et al. Multicentric breast cancer as a new indication for sentinel node biopsy - a multiinstitutional validation study. Abstract book of 5th European Breast Cancer Conference. Eur. J. Cancer 4(2), 78 (N.119) (2006).
84. Mertz L, C Mathelin, C Marin et al. Subareolar injection of 99m-Tc sulfur colloid for sentinel nodes identification in multifocal invasive breast cancer. Bull. Cancer 86(11), 939-945 (1999).
85. Schrenk P, Wayand W. Sentinel-node biopsy in axillary limph-node staging for patients with multicentric breast cancer. Lancet 357 (9250), 122 (2001).
86. Kim HJ, Heerdt AS, Cody HS et al. Sentinel lymph node drainage in multicentric breast cancers. Breast J. 8(6), 356-361 (2002).
87. Feldman SM, Krag DN, McNally RK et al. Limitation in gamma probe localization of the sentinel node in breast cancer patients with large excisional biopsy. J. Am. Coll. Surg. 188, 248-254 (1999).
88. Haigh PI, Hansen NM, Giuliano AE. Biopsy method and excision volume do not affect success rate of subsequent sentinel lymph node dissection in breast cancer. Ann. Surg.. Oncol. 7(1), 21-27 (2000).
89. Wong S, Edwards M, Chao C et al. The effect of prior breast biopsy method and concurrent definitive breast procedure on success and accuracy of sentinel lymph node biopsy. Ann. Surg, Oncol. 9, 272-277 (2002).
90. Luini A, Galimberd V, Gatti G et al. The sentinel lymph node biopsy after previous breast surgery: preliminary results on 543 patients treated at the European Institute of Oncology. Breast Cancer Res. Treat. 89, 159-163 (2005).
91. Intra M, Trifiro G, Viale G et al. Second biopsy of axillary sentinel lymph node for reappearing breast cancer after previous sentinel lymph node biopsy. Ann. Surg, Oncol. 12(11), 895-899 (2005).
92. Jones JL, Zabicki K, Christian RL et al. A comparison of sentinel lymph node biopsy before and after neoadjuvant chemotherapy: timing is important. Am. J. Surg. 190(4), 517-520 (2005).
93. Nason KS, Anderson BO, Byrd DR et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer-89, 2187-2194 (2000).
94. Fernandez A, Cortes M, Benito E et al. Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy scheme. Nucl. Med. Commun. 22, 361-366 (2001).
95. Breslin TM, Cohen L, Sahin A et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J. Clin. Oncol. 18, 3480-3486 (2000).
96. Mamounas EP, Brown A, Anderson S et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: result from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J. Clin. Oncol. 23(N12), 2694-2702 (2005).
97. Khan A, Sabel M, Nees A et al. Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy. Ann. Surg. Oncol. 12(9), 697-704 (2005).
98. Pendas S, Dauway E, Giuliano R et al. Sentinel node biopsy in ductal carcinoma in situ patients. Ann. Surg. Oncol. 7(1), 15-20 (2000).
99. Klauber-DeMore N, Tan L, Liberman L et al. Sentinel lymph node biopsy: is it indicate in patients with high-risk ductal carcinoma-in-situ and ductal carcinomain-situ with microinvasion? Ann. Surg. Oncol. 7(9), 636-642 (2000).
100. Yen TW, Hunt KK. Ross MI et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J. Am. Coll. Surg. 200(4), 516-526 (2005).
101. Zavagno G, Carcoforo R Marconato R et al. Role of axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. BMC Cancer 5(1), 28 (2005).
102. Veronesi P, Intra M, Vento AR et al. Sentinel lymph node biopsy for localized ductal carcinoma in situ? Breast 14(6), 520-522 (2005).
103. Gentilini O, Cremonesi M, Trifirò G et al. Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann. Oncol. 15, 1348-1351 (2004).
104. Cserni G, Gregari D, Merletti F et al. Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br. J. Surg. 91, 1245-1252 (2004).
105. Hwang RF, Krishnamurthy S, Hunt KK et al. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann. Surg. Oncol. 10, 248-254 (2003).
106. Van Zee KJ, Manasseh DM, Bevilacqua JL et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann. Surg. Oncol. 10. 1140-1151 (2003).
107. Viale G. Maiorano E, Pruneri G et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann. Surg. 241(2), 319-325(2005).
108. Degnim AC, Griffith KA, Sabel MS et al. Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. A metaanalysis. Cancer 98, 2307-2315 (2003).
109. Millis RR, Springall R, Lee AH et al. Occult axillary lymph node metastases are of no prognostic significance in breast cancer. Br. J. Cancer 86, 396-401 (2002).
110. Colleoni M, Rotmensz N, Peruzzotti G et al. Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. J. Clin. Oncol. 23(7), 1379-1389 (2005).